Last reviewed · How we verify
BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer
Approved treatments
- Talzenna · Pfizer Inc.
PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers.
Clinical guidelines
- FDA label — any
TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (g BRCA m) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer patent landscape — cliff calendar, originator estates, attackable patents
- BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer treatment landscape brief
- BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer treatment updates RSS
Frequently asked questions about BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer
What drugs treat BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer?
Tracked treatments include Talzenna.
What is the treatment for BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer?
Standard treatment for BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer includes Talzenna. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer?
FDA label publishes guidelines for BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer. 1 guideline references tracked.
Related
- Treatment landscape: BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer patent cliff · BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer CI report
- Treatment: Talzenna · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing